1. A double-edged sword. Issue 3 (September 2020) Authors: Vandebotermet, Martijn; Staels, Frederik; Giovannozzi, Simone; Delforge, Michel; Tousseyn, Thomas; Steelandt, Thomas; Corveleyn, Anniek; Meyts, Isabelle; Maertens, Johan; Yserbyt, Jonas; Schrijvers, Rik Journal: Breathe Issue: Volume 16:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Issue 5 (29th February 2020) Authors: Goldman‐Mazur, Sarah; Jurczyszyn, Artur; Castillo, Jorge J.; Waszczuk‐Gajda, Anna; Grząśko, Norbert; Radocha, Jakub; Bittrich, Max; Kortüm, K. Martin; Gozzetti, Alessandro; Usnarska‐Zubkiewicz, Lidia; Davila Valls, Julio; Jayabalan, David S.; Niesvizky, Ruben; Kelman, Julia; Coriu, Daniel; Rosiño... Journal: American journal of hematology Issue: Volume 95:Issue 5(2020:May) Page Start: 503 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis. (14th June 2017) Authors: Moreau, Philippe; Dimopoulos, Meletios A.; Richardson, Paul G.; Siegel, David S.; Cavo, Michele; Corradini, Paolo; Weisel, Katja; Delforge, Michel; O'Gorman, Peter; Song, Kevin; Chen, Christine; Bahlis, Nizar; Oriol, Albert; Hansson, Markus; Kaiser, Martin; Anttila, Pekka; Raymakers, Reinier; Joa... Journal: European journal of haematology Issue: Volume 99:Number 3(2017) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Being a hematologist. (August 2014) Authors: Delforge, Michel Journal: International journal of hematologic oncology Issue: Volume 3:Number 4(2014) Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Being a hematologist. (August 2014) Authors: Delforge, Michel Journal: International journal of hematologic oncology Issue: Volume 3:Number 4(2014) Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study. (December 2014) Authors: T'Seyen, Stef; Pans, Steven; Laenen, Anouchka; Devos, Timothy; Dierickx, Daan; Schoemans, Hélène; Delforge, Michel Journal: International journal of hematologic oncology Issue: Volume 3:Number 6(2014) Page Start: 387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice. Issue 1 (7th December 2018) Authors: Hulin, Cyrille; de la Rubia, Javier; Dimopoulos, Meletios A.; Terpos, Evangelos; Katodritou, Eirini; Hungria, Vania; De Samblanx, Hadewijch; Stoppa, Anne‐Marie; Aagesen, Jesper; Sargin, Deniz; Sioni, Anastasia; Belch, Andrew; Diels, Joris; Olie, Robert A.; Robinson, Don; Potamianou, Anna; van de ... Journal: Health science reports Issue: Volume 2:Issue 1(2019) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Issue 10192 (6th July 2019) Authors: Moreau, Philippe; Attal, Michel; Hulin, Cyrille; Arnulf, Bertrand; Belhadj, Karim; Benboubker, Lotfi; Béné, Marie C; Broijl, Annemiek; Caillon, Hélène; Caillot, Denis; Corre, Jill; Delforge, Michel; Dejoie, Thomas; Doyen, Chantal; Facon, Thierry; Sonntag, Cécile; Fontan, Jean; Garderet, Laurent; ... Journal: Lancet Issue: Volume 394:Issue 10192(2019) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice. (5th September 2018) Authors: Terpos, Evangelos; Katodritou, Eirini; de la Rubia, Javier; Hungria, Vania; Hulin, Cyrille; Roussou, Maria; Delforge, Michel; Bries, Greet; Stoppa, Anne‐Marie; Aagesen, Jesper; Sargin, Deniz; Belch, Andrew; Ahlberg, Lucia; Diels, Joris; Olie, Robert A.; Robinson, Don; Spencer, Mike; Potamianou, A... Journal: European journal of haematology Issue: Volume 101:Number 4(2018) Page Start: 556 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗